drugset
drugset / Trial / NCT02003313

Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine

NCT02003313 ↗

Phase 3 Completed 1260 enrolled Beijing Minhai Biotechnology Co., Ltd
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this double-blind study is to evaluate the safety, reactogenicity and immunogenicity of Group A,C,Y and W135 Meningococcal Polysaccharide Vaccine in 2 to 30 years-old Children and Adults. All subjects will receive 1 dose of Group A,C,Y and W135 Meningococcal Polysaccharide Vaccine.

Timeline

Start
2013-11
Primary completion
2015-05
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator CCX140-B Small molecule 0.5 ml Intramuscular
Subject Tranexamic Acid Small molecule 0.5 ml Intramuscular

Indications

meningitis